BRAF and Miyoshi myopathy: In addition to immune checkpoint inhibitors (ICI), targeted treatment (TT) with a combination of BRAF and MEK inhibitors (BRAFi+MEKi) is one of the mainstays of therapy in patients with BRAF-mutated MM.